These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24098532)

  • 1. Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.
    Pryde DC; Jones LH; Gervais DP; Stead DR; Blakemore DC; Selby MD; Brown AD; Coe JW; Badland M; Beal DM; Glen R; Wharton Y; Miller GJ; White P; Zhang N; Benoit M; Robertson K; Merson JR; Davis HL; McCluskie MJ
    PLoS One; 2013; 8(10):e76557. PubMed ID: 24098532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.
    McCluskie MJ; Pryde DC; Gervais DP; Stead DR; Zhang N; Benoit M; Robertson K; Kim IJ; Tharmanathan T; Merson JR; Davis HL
    Int Immunopharmacol; 2013 May; 16(1):50-6. PubMed ID: 23562759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.
    McCluskie MJ; Thorn J; Mehelic PR; Kolhe P; Bhattacharya K; Finneman JI; Stead DR; Piatchek MB; Zhang N; Chikh G; Cartier J; Evans DM; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Apr; 25(2):518-27. PubMed ID: 25737198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.
    Arutla V; Leal J; Liu X; Sokalingam S; Raleigh M; Adaralegbe A; Liu L; Pentel PR; Hecht SM; Chang Y
    ACS Comb Sci; 2017 May; 19(5):286-298. PubMed ID: 28383252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-nicotine vaccines: Comparison of adjuvanted CRM197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human primates.
    McCluskie MJ; Thorn J; Gervais DP; Stead DR; Zhang N; Benoit M; Cartier J; Kim IJ; Bhattacharya K; Finneman JI; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Dec; 29(2):663-671. PubMed ID: 26404190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new strategy for improved nicotine vaccines using conformationally constrained haptens.
    Meijler MM; Matsushita M; Altobell LJ; Wirsching P; Janda KD
    J Am Chem Soc; 2003 Jun; 125(24):7164-5. PubMed ID: 12797775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influencing Antibody-Mediated Attenuation of Methamphetamine CNS Distribution through Vaccine Linker Design.
    Gooyit M; Miranda PO; Wenthur CJ; Ducime A; Janda KD
    ACS Chem Neurosci; 2017 Mar; 8(3):468-472. PubMed ID: 27958709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
    Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
    Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.
    Jalah R; Torres OB; Mayorov AV; Li F; Antoline JF; Jacobson AE; Rice KC; Deschamps JR; Beck Z; Alving CR; Matyas GR
    Bioconjug Chem; 2015 Jun; 26(6):1041-53. PubMed ID: 25970207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice.
    Thorn JM; Bhattacharya K; Crutcher R; Sperry J; Isele C; Kelly B; Yates L; Zobel J; Zhang N; Davis HL; McCluskie MJ
    Vaccines (Basel); 2017 May; 5(2):. PubMed ID: 28513561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.
    McCluskie MJ; Evans DM; Zhang N; Benoit M; McElhiney SP; Unnithan M; DeMarco SC; Clay B; Huber C; Deora A; Thorn JM; Stead DR; Merson JR; Davis HL
    Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):184-96. PubMed ID: 27121368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a multivalent peptide vaccine for nicotine addiction.
    Zeigler DF; Roque R; Clegg CH
    Vaccine; 2019 Mar; 37(12):1584-1590. PubMed ID: 30772068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.
    Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR
    J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.
    Matyas GR; Mayorov AV; Rice KC; Jacobson AE; Cheng K; Iyer MR; Li F; Beck Z; Janda KD; Alving CR
    Vaccine; 2013 Jun; 31(26):2804-10. PubMed ID: 23624097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.
    Laudenbach M; Tucker AM; Runyon SP; Carroll FI; Pravetoni M
    Vaccine; 2015 Nov; 33(46):6332-9. PubMed ID: 26409811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure.
    de Villiers SHL; Lindblom N; Kalayanov G; Gordon S; Baraznenok I; Malmerfelt A; Marcus MM; Johansson AM; Svensson TH
    Vaccine; 2010 Mar; 28(10):2161-2168. PubMed ID: 20060511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Small Molecular Property on Antibody Response.
    Wen K; Bai Y; Wei Y; Li C; Shen J; Wang Z
    J Agric Food Chem; 2020 Sep; 68(39):10944-10950. PubMed ID: 32854496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse.
    Collins KC; Janda KD
    Bioconjug Chem; 2014 Mar; 25(3):593-600. PubMed ID: 24521489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.
    Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C
    Biomaterials; 2017 Sep; 138():46-56. PubMed ID: 28551462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.